logo

Intellia Therapeutics, Inc. (NTLA)



Trade NTLA now with
  Date
  Headline
9/16/2022 7:18:49 AM Intellia Therapeutics, Regeneron Pharma Announce Positive Interim Results From Phase 1 Clinical Trial Of NTLA-200
9/16/2022 7:10:21 AM Intellia Therapeutics Announces Positive Interim Phase 1/2 Clinical Data For NTLA-2002 For Hereditary Angioedema
6/24/2022 7:38:54 AM Intellia Presents Updated Interim Data From Phase 1 Study Of NTLA-2001 For Treatment Of Transthyretin Amyloidosis
6/24/2022 7:33:43 AM Intellia And Regeneron Present Addnl Positive Interim Data From Phase 1 Study Of NTLA-2001 For ATTR Amyloidosis
2/15/2022 4:41:13 PM Wedbush Reiterates Intellia Therapeutics, Inc. (NTLA) At Neutral With $108 Price Target
12/20/2021 7:40:04 AM Intellia Therapeutics Appoints Derek Hicks As Chief Business Officer
12/13/2021 7:39:55 AM Intellia Therapeutics Doses First Patient In Phase 1/2 Clinical Trial Of NTLA-2002 For Hereditary Angioedema
11/22/2021 7:36:38 AM Intellia Therapeutics Expands Phase 1 Study Of NTLA-2001 For Adults With Transthyretin Amyloidosis With Cardiomyopathy
9/16/2021 8:03:22 AM Intellia Therapeutics: FDA Accepts NTLA-5001 IND For Acute Myeloid Leukemia
6/26/2021 11:19:40 AM Intellia, Regeneron Announce Data Showing Deep Reduction In Disease-Causing Protein After Single Infusion Of NTLA-2001
6/24/2021 7:31:55 AM Intellia Therapeutics Names James Basta EVP, General Counsel And Corporate Secretary